Member Info for marik

Bill Gates and the WHO are right, the way to resolve the covid problem is to vaccinate more of the global population. Vaccines, testing and therapeutics are the way forward.

https://au.finance.yahoo.com/news/bill-gates-has-a-warning-for-the-world-urges-quick-action-222338128.html

That would explain why they went for IFN-alpha, it's because they assumed that it is similar to IFN-beta (what a mistake to make by Professor Weber).

When Professor Friedemann Weber says "IFN-beta is more powerful. But who knows!", there in lies the problem. Professor Sir Stephen Holgate considers IFN-beta to be more powerful than IFN-alpha. That's why IFN-beta therapy has been the focus of research for so long.

I've noted quite a few comments on this paper [1] in reference to Synairgen. There are a few points that have been missed and the paper is positive for SNG001.

Here are the few key points to note.

1. first part of the study finds that Omicron had a low activation levels against IFN-beta (special emphasis by the authors).
2. they go on to present results of exogenous IFN-alpha (they presented IFN-alpha data but should have in theory gone straight for IFN-beta).

Another reason that the authors should have chosen IFN-beta for testing is because in vivo antibodies against interferon-alpha would neutralise its effect. But that isn't the case for IFN-beta.

In summary, only the first part of the paper is relevant for Synairgen i.e. Omicron induces low levels of IFN-beta. Which leads us to assume that higher levels of exogenous IFN-beta would have been beneficial.

https://www.biorxiv.org/content/10.1101/2022.01.20.476754v1

For Eurasia Mining, it's business as usual. We should all realise that Eurasia Mining is a UK registered company since 1996 and it is NOT Russian. Despite current tensions between US and Russia the worst case scenario are targeted sanctions.

Firstly, let's have a look at the impact on the share price on the last serious Russian-Ukrainian issue. Historical sanctions had zero impact on the Eurasia Mining share price. For example; the annexation of the Crimea by Russia (20 Feb 2014 – 26 Mar 2014) resulted in no significant change to the share price (0.43-0.47px).

Although experts differ on their opinion on what is likely to happen, Dr Fred Kagan states that there are insufficient troops amassed at the border for Russia to enter Ukraine and hold meaningful positions. With resistance likely to be very strong, it would be a no win situation for any parties concerned. With that being said, the chances of invasion are not high especially considering the eight-point draft treaty released by Russia’s foreign ministry recently asking for certain legal criteria to be met to avoid any conflict. Although, controversial in nature, there will almost certainly be a carefully crafted diplomatic solution.

Furthermore, *IF* there are sanctions (and that is a very big and bold IF), it would make little sense for the UK Gov to place sanctions that would cause more issues for a UK company than Russian ones. Any sanctions would have to be targeted and the current situation is likely to subside in the coming weeks.

It's business as usual for Eurasia Mining

GLA

Time is almost upon us with the final results and will take Synairgen in to a different league.

GLA all this morning and if its not tomorrow then anytime this week.

£5.70+ here we come.

With RNS £5.70 on Monday but will continue to rise the next day to £6.30. If there is any mention of EUA already submitted or stockpiling then could be much higher.

@gggg21, there seems to be some position taking today.

Data from Denmark *provisionally* shows it has similar hospitalisation compared to other lineages, but there is a question that remains on how it fairs with vaccines and infectiousness. We are finding in Denmark that whilst the dominant BA.1 freq. has dropped, BA.2 has increased from 20% of all covid cases to 45% in approx. 2 weeks.

Yes I am aware, and possibly others are too, that BA.2 isn't new (around since early Dec). It's making news because it's now becoming dominant in some countries and has a higher transmission. It has no SGTF and makes it fly under the radar and therefore designated as Variant Under Investigation.

I suspect there to be news very soon. Judging by all the information coming from the company, they look very bullish about it. I would think that the news is soon and Monday gives the market time to absorb and react over a few days. Could have a TR-1 RNS soon but let's wait for ManicMonday2.0 RNS

Nothing disappointing about it. Sky news reported it today as did other news:

"Omicron 'sub-lineage' BA.2 designated as COVID variant under investigation, says UKHSA"

https://news.sky.com/story/omicron-sub-lineage-ba-2-designated-as-covid-variant-under-investigation-says-ukhsa-12521718

It reduces two doses of the Pfizer vaccine to 30 percent effectiveness, with AstraZeneca potentially down to zero.

BA.2 has been designated as COVID variant under investigation by the UKHSA.

They also make comments on the therapeutics side, where they are " already begun to build the pipeline on other drugs, including Velcade ($1.2bn sales) and Paclitaxel ($2.96bn sales). " and regarding AVA6000 they state they "started dosing their first patients and currently at a stage to test safety and tolerability."

For these kind of meetings, they will have to show topline data of the safety and tolerability. They must be confident of the results so far.

"If the trials conclude well and results are very good then your 80% loss will become a min 80% gain."

@munchbox54 agreed, the OP answered their own question

Any data from non-US trials has to be submitted for review to the FDA.

" FDA require any available in-human data to be submitted for trial approval. Given the FDA's 30 day response time and known date of first dosing, this would have been available for inclusion."

@benbenbenben absolutely agree, this has to be included. The first site started recruiting as per the clinical trials website.

@Hullaballoola if you need further info you can DM me on https://twitter.com/marik_investor

Thanks @Oakleaf. That is VERY telling.

"Great post Marik... Worth reminding everyone why we are here and reasons to top up sub 80"

@Hullaballoola you are welcome. It's always worth refreshing the information. I realised that in some cases people glance and forget information and/or just don't understand timeframes etc.

It's great to the see the Chief Commercial Officer putting out the post.